|
|
|
|
|
|
|
M Tue W Th F |
|
14 July, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
Biogen's track record with Alzheimer's can be best described as wildly uneven, and the big biotech is facing another hurdle in the disease with diranersen. The tau-targeting drug fared better with patients on the low dose than on the high dose, perplexing everyone involved. Ryan Cross has more on the data that were released today at the Alzheimer’s Association International Conference in London. |
|
|
|
Alex Hoffman |
Copy Chief and News Editor, Endpoints News
|
|
|
|
|
|
|
by Ryan Cross
|
LONDON— Biogen's attempt to treat Alzheimer's by going after a protein that forms toxic tangles in the brain showed some of the strongest proof... | |
|
|
|
 |
|
Chai Discovery co-founders Matthew McPartlon (L) and Joshua Meier at last year's Endpoints 11 event (Mike Last for Endpoints News) |
|
|
|
by Kyle LaHucik
|
Chai Discovery, one of the hottest startups in the AI-generated drug discovery landscape, has corralled $400 million in a Series C that triples its paper... | |
|
|
|
|
|
 |
|
Ivana Magovčević-Liebisch, Draig Therapeutics CEO |
|
|
|
by Ayisha Sharma
|
Draig Therapeutics has secured$65 million in an oversubscribed Series B raise to advance a pipeline of neuropsychiatry drugs, including its lead depression program designed... | |
|
|
|
 |
|
|
|
by ENDPOINTS |
Plus, news about subcutaneous Leqembi, WuXi AppTec and Q32 Bio. 📊 Erasca targets $550M for KRAS drugs: The biotech's public
offeringcame after it... | |
|
|
|
|
|
|
by Lei Lei Wu
|
Lyora Therapeutics will try to revive several early-stage genetic eye disease programs previously held by Editas Medicine and Biogen. The biotech was co-founded by Luk... | |
|
|
|
|
|
